CoreMedic announced that it picked up new funding in a Series B extension to support its transcatheter mitral valve repair ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...

"Don't be afraid to go to the doctor and get checked. But if you are it's ok. Just make sure you do it afraid, but ultimately, get it done," she says.

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

IRVINE, Calif. - Edwards Lifesciences (NYSE:EW) reported fourth quarter earnings and revenue that beat analyst expectations, sending its shares up 4.2% in after-hours trading on Tuesday.

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare ...

Although any dog can develop health conditions, these breeds are the least likely to have ones that will break the bank.